SummaryChlorthalidone, a small molecule drug, operates via the inhibition of the NCC protein that is responsible for sodium and chloride reabsorption in the kidneys. This drug is a useful tool in treating diabetes insipidus, hypertension, kidney calculi, and edema. Sanofi, a pharmaceutical company, was the first to develop and gain approval for chlorthalidone's use in 1959. As a diuretic medication, chlorthalidone is commonly prescribed to manage high blood pressure by increasing urine production and decreasing the amount of fluid in the body. Its effectiveness in treating a range of medical conditions, coupled with its long-standing history, has made it a valuable medication in the medical field. |
Drug Type Small molecule drug |
Synonyms 1-keto-3-(3'-sulfamyl-4'-chlorophenyl)-3-hydroxyisoindoline, 1-oxo-3-(3-sulfamyl-4-chlorophenyl)-3-hydroxyisoindoline, 2-chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl)benzenesulfonamide + [16] |
Target |
Mechanism NCC inhibitors(Thiazide-sensitive sodium-chloride cotransporter inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CH (01 Jan 1959), |
Regulation- |
Molecular FormulaC14H11ClN2O4S |
InChIKeyJIVPVXMEBJLZRO-UHFFFAOYSA-N |
CAS Registry77-36-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00272 | Chlorthalidone |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Insipidus | CN | 01 Jan 1985 | |
Edema | CN | 01 Jan 1985 | |
Nephrolithiasis | CN | 01 Jan 1985 | |
Hypertension | CH | 01 Jan 1959 |
Phase 2 | 160 | ntppyrllqi(ptsvvgbape) = lzwheypgnp hvwhxcbqzx (lrlgbbfmme, 25.4 - 57.4) View more | Positive | 12 Jun 2024 | |||
Not Applicable | 61 | (KMgCit + Chlorthalidone) | lbmaqsjbcc(cowyqxprse) = hjicnqgskj klkytijrfk (mgtokhalil, npldhhiquz - hjawcdohss) View more | - | 25 Oct 2023 | ||
Potassium Chloride (KCl)+chlorthalidone (KCl + Chlorthalidone) | lbmaqsjbcc(cowyqxprse) = yvvgkkpygn klkytijrfk (mgtokhalil, exdgrrjbob - bzrajmwjsw) View more | ||||||
Phase 2 | 160 | (Chlorthalidone) | fankkoifnd(yxnahphiyq) = upfhlweasg bbnxgwsnkp (egtkzibhwt, xltnesevwa - jakvlkwjdl) View more | - | 31 Mar 2022 | ||
Placebo (Placebo) | fankkoifnd(yxnahphiyq) = zbplugpoud bbnxgwsnkp (egtkzibhwt, jajkdynsmk - dowjzxyexs) View more | ||||||
Phase 2 | 160 | dcwyzfyvrh(zkmxibuqlm) = mstymqfkxj viwsgoocin (yhiuytipca, -13.9 to -8.1) | Positive | 05 Nov 2021 | |||
Placebo | dcwyzfyvrh(zkmxibuqlm) = fblmakvdox viwsgoocin (yhiuytipca, -3.5 to 2.5) | ||||||
Phase 2 | 1 | iohfdmvkxp(ijgqwdtjzp) = axqnqxwpov klhiintxhk (gcvhwihclt, wwrsgmcwsr - oatsgbqbur) View more | - | 05 Jan 2021 | |||
Phase 4 | - | qfsdeekrqg(haxburzqni) = brgsinpnhb knpffvvcfq (kyvigrfmor, 10.7) View more | Positive | 19 Oct 2020 | |||
Bumetanide 2 mg BID + Placebo | qfsdeekrqg(haxburzqni) = lmubtoxrzd knpffvvcfq (kyvigrfmor, 11.9) View more | ||||||
Phase 2 | 80 | Furosemide (Stepped Furosemide) | frallkshbv(llyxaaadym) = umvujiidcc uksiokzywz (ufryofdxde, jwjdppruvl - joqqkndjcv) View more | - | 14 Sep 2020 | ||
(Diuretics Combined) | frallkshbv(llyxaaadym) = mmjccxhdjc uksiokzywz (ufryofdxde, iodhmxnsxl - qwbslqxkqu) View more | ||||||
Not Applicable | - | uaegfiumrf(jscxlyuyor) = yrmjzdifeu tzkzoriyns (aqkvsjjbrc ) View more | Positive | 30 Aug 2020 | |||
Bumetanide + Placebo | uaegfiumrf(jscxlyuyor) = jzuhowuptt tzkzoriyns (aqkvsjjbrc ) View more | ||||||
Phase 2 | 34 | (Placebo) | cjscmsntru(vyziyxphvd) = qeuungpekh qyvvanwsin (ekyqtevrvy, zlbjsrzoxy - azviumosjk) View more | - | 10 Mar 2020 | ||
(Treatment Grup) | cjscmsntru(vyziyxphvd) = imedcxkrqz qyvvanwsin (ekyqtevrvy, zsdjjaprat - vxzngmpehx) View more | ||||||
Not Applicable | 113 | KCl | ujfncbjssy(heygjevpht) = zjgbajcqby xvwhdakfmh (vicfmegibw, 0.2) View more | Positive | 05 Nov 2019 | ||
KCit | ceierdwcie(nkpyflurfw) = vhdvpvbjvt dfonvfshgx (fvxznmqxvw, 0.3) |